aspirin - Profile

What are the generic drug sources for aspirin and what is the scope of patent protection?

Aspirin is the generic ingredient in fifty-three branded drugs marketed by Hesp, Plx Pharma, Bayer, Savage Labs, Lgm Pharma, Mpp Pharma, Watson Labs, Allergan, Sandoz, Actavis Elizabeth, Fosun Pharma, Halsey, Hikma Intl Pharms, Ivax Pharms, Puracap Pharm, Quantum Pharmics, Strides Pharma, Lannett, Dr Reddys Labs Sa, Novitium Pharma, Stevens J, Sun Pharm Industries, Chartwell Rx, Bausch, Galt Pharms, Alra, Xanodyne Pharm, Ivax Sub Teva Pharms, Teva, Genus, Novast Labs, Oxford Pharms, Meda Pharms, Ingenus Pharms Nj, Boehringer Ingelheim, Amneal Pharms, Ani Pharms, Barr, Chartwell Molecular, Dr Reddys, Glenmark Speclt, Micro Labs, Ph Health, Sun Pharm, Zydus Pharms, Schwarz Pharma, Abbott, Par Pharm, Medpointe Pharm Hlc, Mcneil, Robins Ah, Genus Lifesciences, Actavis Labs Fl Inc, Epic Pharma Llc, Endo Operations, Roxane, Sanofi Aventis Us, Bristol Myers Squibb, and Aaipharma Llc, and is included in eighty-nine NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aspirin has twenty patent family members in nine countries.

There is one tentative approval for this compound.

Summary for aspirin

International Patents:	20
US Patents:	6
Tradenames:	53
Applicants:	59
NDAs:	89
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for aspirin

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for aspirin

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for ASPIRIN

Applicant	Application No.	Strength	Dosage Form
		325MG;40MG	TABLET;ORAL
		81MG;40MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for aspirin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hesp	DURLAZA	aspirin	CAPSULE, EXTENDED RELEASE;ORAL	200671-001	Sep 4, 2015		DISCN	Yes	No
Plx Pharma	VAZALORE	aspirin	CAPSULE;ORAL	203697-002	Feb 26, 2021		OTC	Yes	No
Plx Pharma	VAZALORE	aspirin	CAPSULE;ORAL	203697-002	Feb 26, 2021		OTC	Yes	No			Y
Plx Pharma	VAZALORE	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013		OTC	Yes	Yes

Expired US Patents for aspirin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Plx Pharma	VAZALORE	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013
Plx Pharma	VAZALORE	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013
Plx Pharma	VAZALORE	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013

International Patents for aspirin

Country	Patent Number	Title	Estimated Expiration
Mexico	2014003890	PORTADORES DEPENDIENTES DEL PH PARA LA LIBERACION DIRIGIDA DE PRODUCTOS FARMACEUTICOS A LO LARGO DEL TRACTO GASTROINTESTINAL, COMPOSICIONES DE LOS MISMOS, Y FABRICACIÓN Y USO DE LAS MISMAS. (pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME.)
South Korea	20200118219	위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법 (pH PH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT COMPOSITIONS THEREFROM AND MAKING AND USING SAME)
Japan	6368645
Mexico	340951

Supplementary Protection Certificates for aspirin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0984957	2012/048	Ireland		PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
0984957	122012000017	Germany		PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812

Aspirin: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Aspirin (acetylsalicylic acid) remains a foundational drug in cardiovascular therapy despite the emergence of newer therapies. Market analysis indicates a mature but still expanding market driven by aging populations, evolving indications, and regulatory environments. Investment prospects are influenced by patent expirations, generic competition, and ongoing clinical research. This report provides a comprehensive review of the current market landscape, future growth drivers, competitive dynamics, and financial projections for aspirin.

---

What Is the Market Size and Growth Outlook for Aspirin?

Parameter	Details
Global market size (2022)	USD 2.5 billion [1]
Compound Annual Growth Rate (CAGR, 2023–2028)	3.2% [2]
Major markets	North America, Europe, Asia-Pacific
Market segments	Over-the-counter (OTC), Prescription, Generic

Market Drivers

• Increasing prevalence of cardiovascular disease (CVD), stroke, and myocardial infarction.
• Growing awareness of aspirin’s role in primary and secondary prevention.
• Expanding use in conditions such as colorectal cancer prevention and COVID-19-related thrombotic complications.

Market Restraints

• Competition from alternative antiplatelet agents (e.g., clopidogrel, ticagrelor).
• Safety concerns, including bleeding risks, especially in elderly populations.
• Regulatory shifts limiting OTC availability in some regions.

---

What Are the Key Market Dynamics Affecting Aspirin?

Competitive Landscape

Players	Market Share (2022)	Notes
Bayer (Aspergum, Bufferin)	45%	Leading global supplier, strong brand
Local generics manufacturers	50%	Significant OTC presence in emerging markets
Brandless/Non-branded OTC	5%	Increasing due to cost-sensitivity

Patent and Regulatory Environment

• Patent Expiry: Original patents for patented formulations expired in the early 2000s, leading to widespread generics.
• Regulatory Changes:
  • In the US, FDA emphasized risk-benefit balance, urging cautious OTC use.
  • In Europe, aspirin remains available OTC with similar guidelines.
  • Certain markets (e.g., Japan) have more restrictive OTC access.

Scientific Advances and Clinical Guidelines

• Recent studies reinforce aspirin's role in secondary prevention but question primary prevention use in low-risk populations.
• Guidelines:
  • American College of Cardiology/American Heart Association (2022) recommends aspirin for secondary prevention.
  • Use in primary prevention is increasingly conservative, affecting market size.

Emerging Markets

• Greater access and increasing healthcare infrastructure in Asia-Pacific drive growth.
• Local manufacturing reduces costs and supports market expansion.

Pricing & Reimbursement Policies

• OTC prices vary widely; high in developed markets and highly regulated.
• Reimbursement coverage is limited primarily to prescription aspirin for specific indications.

---

What Is the Financial Trajectory of Aspirin?

Revenue Trends (2020–2025)

Year	Global Revenue (USD Billion)	Growth (%)	Drivers
2020	2.2	—	Established market, stable usage
2021	2.3	4.5%	Continued aging populations; secondary prevention uptake
2022	2.5	8.7%	Pandemic-related thrombotic complication concerns
2023	2.6	4%	Stabilization; competition from newer agents
2024	2.7	3.8%	Market maturity; regulatory and safety adjustments
2025	2.8	3.7%	Slight growth due to emerging markets

Profitability & Cost Structure

• Gross margins: Approx. 60%–70%, primarily driven by generic manufacturing.
• R&D expenditure: Minimal for branded aspirin; focus on clinical studies for new indications.
• Pricing trends: Slight declines in developed markets; stable or increased in emerging markets due to local manufacturing.

Future Revenue Drivers

• Expansion into adjunct indications: Colorectal cancer prevention, COVID-19-related indications.
• Development of combination products, e.g., aspirin + statins.
• Adoption in targeted populations with high thrombotic risk.

---

How Do Competition and Innovation Influence Aspirin's Financial Trajectory?

Factor	Impact
Generic proliferation	Reduces prices, compresses margins, but sustains volume
Alternative therapies	Clopidogrel, ticagrelor, prasugrel gaining traction; some replacing aspirin
Formulation innovations	Chewable, effervescent, and low-dose formulations expanding access
Biologics and novel agents	Pose long-term threat, but currently limited impact on aspirin sales

---

What Are the Regulatory and Policy Trends?

Region	CurrentStatus	Influence on Market
US	BPA (Blood Pressure Algorithm) emphasizes secondary prevention	Reinforces aspirin’s prescription use
EU	Classifies aspirin as OTC, though cautious with elderly	May limit OTC sales in certain age groups
Japan	Restricted OTC access; prescriptions preferred	Limits market growth in elderly segments
China	Increasing OTC availability; local manufacturing	Supports growth, especially in rural areas

---

Comparison with Alternate Therapies and Market Alternatives

Drug	Indications	Market Share (2022)	Strengths	Limitations
Aspirin	CVD prophylaxis, pain, anti-inflammatory	53%	Cost-effective, well-established	Bleeding risks, declining primary prevention use
Clopidogrel	ACS, PCI, secondary prevention	21%	Fewer bleeding risks, branded options	Costlier, dependence on CYP2C19 metabolism
Ticagrelor	Acute coronary syndromes, secondary prevention	15%	More potent, rapid onset	Higher bleeding risk, costlier
Other agents	Novel anticoagulants (e.g., rivaroxaban, apixaban)	11%	Targeted action, diverse indications	Expensive, specific contraindications

---

Summary of Investment Considerations

Criteria	Assessment
Market Maturity	Stable, mature, with slow growth (3.2% CAGR)
Competition and Patent Landscape	Generics dominate; patent expirations since early 2000s reduce exclusivity
Revenue Potential	Moderate but steady; opportunities in emerging markets and new indications
Regulatory Environment	Conservative; safety concerns limit OTC expansion
Innovation and Pipeline	Minimal R&D for aspirin; focus on combined or novel formulations
Cost Structure and Margins	Favorable due to generic competition

Investment thesis: Aspirin offers a stable revenue stream with predictable cash flows driven primarily by secondary prevention needs and growth in emerging markets. However, declining primary prevention use and competition from newer, targeted agents limit upside potential in the advanced markets.

---

Key Takeaways

• Market Size & Growth: The global aspirin market was valued around USD 2.5 billion in 2022 with a CAGR of approximately 3.2% through 2028, primarily fueled by secondary prevention in cardiovascular disease.
• Market Dynamics: Patent expirations, safety profiles, evolving guidelines, and competition from newer antiplatelet agents shape the landscape. The OTC availability remains region-specific and is subject to regulatory scrutiny.
• Financial Trajectory: Revenues are projected to grow modestly, driven by emerging markets and new clinical applications, but face headwinds from generic price erosion and shifting medical guidelines.
• Competitive Environment: Generics dominate sales; innovations are limited, and newer agents provide alternatives in specific indications.
• Investment Outlook: Stable cash flows aligned with aging populations and secondary prevention needs present opportunities; however, growth is constrained by market maturity and safety concerns.

---

FAQs

Q1: How does the expiry of patents affect aspirin’s market profitability?
Patent expirations have thrusted the market into a commoditized phase dominated by generics, reducing prices but maintaining volume due to high global acceptance and widespread use.

Q2: Are new clinical trials influencing aspirin’s market potential?
Yes. Recent studies supporting its role in colorectal cancer prevention and COVID-19-associated thrombosis could expand indications, impacting future market dynamics.

Q3: What are the main risks to investor returns in aspirin?
Market saturation, regulatory restrictions, safety concerns, and competition from more potent or targeted therapies could limit revenue growth and profitability.

Q4: Which emerging markets present the most growth potential?
China, India, and Southeast Asian countries are key targets due to increasing healthcare infrastructure, rising CVD prevalence, and local manufacturing capabilities.

Q5: Will synthetic or combination formulations influence aspirin’s market share?
Potentially. Combination drugs (aspirin with statins, antihypertensives) may enhance adherence and efficacy, offering incremental market growth, though regulatory and clinical validation remain hurdles.

---

References

[1] MarketResearch.com, “Global Aspirin Market Report,” 2022.
[2] Grand View Research, “Antiplatelet Market Insights,” 2022.